Pharmas’ IRA court losses mount. They keep pursuing them.

Pharma’s fight against the Inflation Reduction Act’s drug price negotiation provisions have fallen a little flat. After nearly a dozen lawsuits, none have been able to hit the target.

Still, the pharma industry persists in its legal pursuit, and many pharma giants have vowed to continue. The Centers for Medicare and Medicaid Services has already completed negotiations for the first 10 drugs selected in Medicare’s 2026 coverage, and executives largely waved off the financial impact in recent earnings calls.